Biogen Analysts Lower Their Forecasts After Q4 Results

Benzinga

13 Feb

Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.

The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.

Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.

Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.

Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.

Biogen shares fell 4.3% to close at $133.43 on Wednesday.

These analysts made changes to their price targets on Biogen following earnings announcement.

Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.
Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.
HC Wainwright & Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.

Considering buying BIIB stock? Here’s what analysts think:

Read This Next:

Top 3 Utilities Stocks That May Collapse In Q1

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2511240528"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511240528\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2511240528?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511240528","market":"hk","top_or_hot":-1,"title":"Biogen Analysts Lower Their Forecasts After Q4 Results","media":"Benzinga","content":"<html><body><p><strong>Biogen Inc</strong> (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.</p>\n<p>The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.</p>\n<p>Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.</p>\n<p>Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.</p>\n<p>Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.</p>\n<p>Biogen shares fell 4.3% to close at $133.43 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.</li>\n<li>Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"569\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121.png 1135w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 3 Utilities Stocks That May Collapse In Q1</strong></li>\n</ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Analysts Lower Their Forecasts After Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Analysts Lower Their Forecasts After Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-02-13 22:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Biogen Inc</strong> (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.</p>\n<p>The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.</p>\n<p>Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.</p>\n<p>Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.</p>\n<p>Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.</p>\n<p>Biogen shares fell 4.3% to close at $133.43 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.</li>\n<li>Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"569\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121.png 1135w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 3 Utilities Stocks That May Collapse In Q1</strong></li>\n</ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.benzinga.com/25/02/43693765/biogen-analysts-lower-their-forecasts-after-q4-results","article_id":"2511240528","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511240528","pubTimestamp":1739455406,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"百健(Biogen)分析师在第四季度业绩公布后下调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.\nThe company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.\nMultiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.\nBiogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.\nRevenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.\nBiogen shares fell 4.3% to close at $133.43 on Wednesday.\nThese analysts made changes to their price targets on Biogen following earnings announcement.\n\nCanaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.\nTruist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.\nHC Wainwright & Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.\n\nConsidering buying BIIB stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 3 Utilities Stocks That May Collapse In Q1","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}